行业顾问撰文主张制药工程项目管理应作为独立学科

By Tobias Kuners of Koenders, managing consultant, Tob Management

Applying general project management to a regulated setting as a variant of PMP or PRINCE2 is one of the most consistent, and most avoidable, causes of cost overrun, schedule slippage, and delayed start-up. Our industry needs a distinct discipline: pharmaceutical engineering project management (PEPM).

For experienced project managers, the practical message is straightforward: pharmaceutical engineering projects fail less often because project management basics are unknown, and more often because the regulated, operational, and transactional layers are not made visible early enough. PEPM therefore requires a project plan that integrates physical delivery, qualification readiness, documentation maturity, resource constraints, and operational handover from the outset.

The framework that follows is organized around three questions an experienced PM should ask continuously: Are the foundational project controls properly resourced? Are the hidden PEPM constraints visible early enough to manage? And does completion include both physical delivery and the regulated transaction trail required for release and operation?

Why PEPM Is A Different Discipline

PEPM covers the design, construction, and qualification of new facilities; the renovation and upgrade of existing ones; and the design, fabrication, and qualification of production equipment, manufacturing lines, packaging lines, and warehouses. Every mid-level or senior PM already knows the standard toolkit — the PMBOK, PRINCE2, Primavera, and the corporate systems built on top of them. Most corporate project management frameworks are themselves derivatives of these standards.

The problem is not that these tools are wrong. The problem is that none of them, on their own, address the recurring failure pattern in pharmaceutical engineering projects: projects that run longer than planned, cost noticeably more than budgeted, and hand over facilities, equipment, or lines that take longer to start up than forecast — which in turn means missed production targets and, further downstream, missed supply commitments. General PM tells you how to plan and track a project. PEPM tells you what a pharmaceutical engineering project specifically breaks on and gives you the instruments to see it coming.

This article sets out that additional layer: the focus, systems, and level of detail that experienced PEPM practitioners recognize as the difference between a project that merely finishes and one that finishes pristine — on scope, on time, at cost, and ready to run. None of it is complicated. All of it is disciplined. The proof is in the execution.

The Foundation You Still Need

PEPM does not replace your general or corporate project management systems — it builds on top of them, and none of what follows works without that foundation in place first:

• Scope: a clear, agreed, and formally signed-off scope
• Team: a defined core team with the appropriate stakeholders represented, and an agreed extended team
• Commitment: explicit agreement on the committed hours of both core and extended team members — vague commitment is the single most common source of resource conflict later in the project
• Cost and planning: a cost controller function and a project planning function. Depending on project size, these may be a dedicated or a shared resource, but the function must exist and be resourced, not folded silently into the PM's own workload.

Safety, or EH&S, is nonnegotiable — that much is not in dispute anywhere in the industry, regardless of project size. What is less consistently applied is the same rigor for cost control and planning. On large projects, cost controlling and project planning are typically built into the project scope as dedicated functions. On midsize and small projects, they are too often left to the project manager to govern personally, on top of everything else. That is a structural flaw in how many organizations design project delivery, not a reflection of the PM's competence. A site that would never run a project without a dedicated safety function should apply the same logic to cost control and planning — whether housed in finance, in engineering, or as its own stand-alone department depends on the size of the site and the volume of projects running through it.

Build the business case before you ask for the function

Take two or three recent projects. Compare the scope, cost, and schedule as agreed at kickoff against what was actually delivered. Net out agreed, reviewed, and approved scope changes (project change notices) — those are legitimate, not slippage. What remains is the cost of not having dedicated cost control and planning: rework, idle facility rental, delayed line start-up, and the lost revenue that follows it. That number is what justifies the function to site leadership.

Instrument 1: Tracking Tasks Before They Become Milestone Delays

In project execution, slippage rarely announces itself. A single delayed task looks minor until three of them converge on the same milestone. The discipline that catches this early is a simple four-quadrant task wheel, reviewed at a fixed cadence — daily for fast-moving construction or commissioning phases, weekly for slower-moving design phases.

Figure 1: Task Definition & Follow-up Wheel (reviewed daily per team cadence)

Each task carries its own record through the wheel: the agreed task and its initiation date; the agreed completion date; if that date slips, the documented reason for delay and the newly agreed date; and, finally, the verified actual completion date. The team meets at the agreed interval, walks the open tasks, and has a short, focused conversation on roadblocks and remediation — not a status theater, a working session. The value is not the wheel itself; it is the discipline of never letting a task go quiet between quadrants.

Instrument 2: Seeing Resource Bottlenecks Before They Bite

Scarce resources — automation engineers, validation specialists, C&Q leads — are shared across projects and departments, and their capacity does not stretch to match ambition. Aligning with procurement for deliveries and supplies, and with warehouse and QA for receipt and release, matters, but the resource bottleneck is usually the one nobody sees until it has already caused a delay.

Map scarce resources on a two-dimensional matrix: time and task duration on one axis, the list of scarce resources — including full-time headcount, planned holidays, and known absence — on the other. Color-code the resulting workload: green up to 100% of capacity, orange up to 140%, red above 140%. The color coding is not decorative; it drives the conversation.

Figure 2: Scarce Resource Workload Matrix (reviewed monthly with site leadership)

Review this matrix with site leadership at least monthly. The purpose of that meeting is to decide, together, which tasks can be brought forward or pushed out without compromising milestone commitments. Done consistently, this single meeting removes the majority of the ad hoc adversarial negotiation that otherwise happens between projects and departments — or between projects competing for the same specialist — because the trade-offs are made visible and decided in one place, on a known cadence.

Instrument 3: Documentation As The Real Critical Path

The tangible parts of a pharmaceutical engineering project — steel, concrete, skids, control panels — are easy to spot and easy to track. What is far less visible, and far more often the actual constraint, is that nearly every activity and milestone is preceded by documentation. Project brief, scope document, project organization, and communication plan; URS, RFI, RFQ, FS, DQ, IQ, OQ, PQ, and PV; P&IDs, layout drawings, schematics; calibration records and test protocols — each one has to be developed, reviewed, and formally agreed to by the relevant stakeholders, and it is normal, not exceptional, for a document to go through a draft, a first, a second, and even a third version before final sign-off.

Figure 3: Document Tracker: Lifecycle stage feeds a live status register per document

A documentation tracker — listing every required document, its version history, its reviewers and approvers, and where it currently sits in the life cycle — functions as an early-warning system for milestone risk long before the physical schedule shows a problem. Most contemporary electronic quality and document management systems can generate this view natively, provided the discipline exists to load and maintain them properly. Where documentation is delivered retrospectively — which regulated environments tolerate more than they should — the tracker is what keeps execution from quietly outrunning its paper trail.

AI In Project Management

AI and large language models are becoming increasingly relevant to project management because they can reduce administrative effort, improve coordination, and support more consistent follow-up across complex project teams. In a PEPM environment, their most immediate value lies in drafting timelines, identifying calendar constraints, capturing agreed actions, assigning follow-up, and helping project teams maintain discipline across recurring meetings and control routines. Their use, however, must be governed deliberately: organizations should define which data sources AI may access, which information must be excluded, who remains accountable for AI-generated outputs, and where human review is mandatory. This is particularly important where internal correspondence may contain confidential development discussions, personnel-sensitive information, or business-sensitive decisions that have not yet been formally communicated.

The effectiveness of this PEPM layer should be measured through a small set of leading and lagging indicators: overdue actions by age and owner, documentation review cycle time, percentage of documents approved on first or second pass, scarce resource overload by function, open project change notices by age, qualification readiness against plan, and time from mechanical completion to operational release. These measures make project health visible before cost and schedule variance become irreversible.

The Chapters General PM Leaves Out

A practical PEPM operating rhythm should define which forums make which decisions, how often they meet, and what input each forum requires. At minimum, project teams should distinguish between day-to-day task follow-up, weekly cross-functional execution review, monthly resource and milestone review with site leadership, and formal change control governance. Without this cadence, the instruments described in this article risk becoming separate trackers rather than one project control system.

Several work streams are consistently under-scoped in generic project plans because they do not look like “the project” until they are missing:

• Quality control: Methods often need to be developed, transferred, and tested; equipment needs to be enlisted, commissioned, and qualified. With the right protocol and QA alignment, some of this can start before facilities are complete, but much of it can only begin once handover to QC has occurred — plan the sequencing explicitly; don't assume it happens by itself.
• Training: Requirements surface in every chapter of the plan, not as a separate track. Define training needs at the very start of plan development or they surface as a milestone risk late, when there is no schedule margin left to absorb them.
• Facilities and maintenance: Spare parts, calibration, inspections, and cleaning — including initial and follow-up calibrations that fall due during a long project — are too often left to the operational department instead of being carried explicitly in the project plan, alongside soft and hard services that continue into the operational period.
• Warehouse, logistics, and supply chain: Receipt of raw materials, intermediates, and excipients and outbound shipments to customers are frequently treated as peripheral to project execution. The systems, protocols, and procedures nonetheless need to be reviewed, approved, and released for use before the project can be considered complete.

None of these are exotic. They are simply easy to leave implicit in a generic project plan — and implicit is where they cause the most damage.

The Traceability Matrix As The Backbone

The PM should also make decision rights explicit. The project team can recommend trade-offs, but site leadership must own priority decisions where several projects compete for the same scarce resource, QA must retain authority over quality system release decisions, and business ownership must remain clear for scope, budget, and benefit realization. Clear decision rights prevent the project manager from becoming the informal escalation path for choices that require functional or business accountability.

The traceability matrix ties project scope and URS through to commissioning, IQ, OQ, and PQ testing, starting from a well-defined list of critical-to-quality attributes. Together with the documentation tracker, it forms the structural backbone of the project plan — the spine onto which every other chapter attaches: equipment release through water run, bouillon run, and product run; facility status from first clean to final clean; EMS in place and in action; QC readiness for incoming goods, intermediate, and final product release testing; training coverage confirmed in every chapter and function; and maintenance functions identified, described, and resourced.

The task wheel, resource matrix, documentation tracker, and traceability matrix should feed the project risk and issue process directly. A delayed document, overloaded validation resource, unresolved action, or missing qualification dependency is not merely a tracker entry; it is a potential risk or issue with an owner, mitigation, due date, and escalation threshold. This linkage prevents parallel control systems from developing and keeps the PM’s attention on decisions that protect the critical path.

A project plan built outward from the traceability matrix and the documentation tracker, rather than one that treats them as compliance paperwork bolted on at the end, is structurally more resistant to the slippage patterns described above — because the dependencies are visible from day one, not discovered at qualification.

Closing The Loop: Completion Means Both Tangible And Transactional

Scope change should be managed as a business and compliance control, not as an administrative afterthought. Every project change notice should state the trigger, business rationale, cost impact, schedule impact, qualification impact, documentation impact, and decision owner. This distinction matters: an approved scope change is not slippage, but an undocumented or late change is a project control failure that will reappear later as rework, budget pressure, or delayed release.

A pharmaceutical engineering project is not finished when the equipment is installed and running. It is finished when every transactional process matches the physical execution and comprehensively captures what actually occurred, meeting ALCOA++ requirements: project change notices captured in a timely manner; the turnover package (TOP) supplied, reviewed, accepted, and released for use; and the operational systems, procedures, and protocols reviewed, accepted, and released for use downstream. A facility that runs but cannot demonstrate this transactional completeness is not, in the PEPM sense, complete.

Practical Takeaways

• Fund and staff cost control and project planning as explicit project functions — even on small and midsize projects — and do not absorb them silently into the PM’s workload.
• Run the four-quadrant task wheel at a fixed cadence, and treat a quiet task — one with no update — as a red flag, not a non-event.
• Put scarce resources on a color-coded workload matrix and review it monthly with site leadership; decide trade-offs in that forum, not in hallway negotiations.
• Stand up a documentation tracker before the project generates its first document, not after the backlog has already formed.
• Scope QC, training, facilities and maintenance, and warehouse/logistics/supply chain explicitly, with owners and timelines — not as departmental afterthoughts.
• Use AI deliberately where it strengthens planning, action follow-up, and coordination — but only within defined privacy, compliance, and information governance boundaries.
• Build the plan outward from the traceability matrix so URS, qualification, and critical to quality (CtQ) attributes stay connected from the outset.
• Define “complete” as tangible and transactional together — TOP, PCNs, and ALCOA++ compliance are part of the deliverable, not paperwork that follows it.

None of this replaces the general project management competence a mid-level or senior PM already brings to the role. It adds the specific focus, systems, and level of detail pharmaceutical engineering projects require — and, applied consistently, it is what separates a project that merely reaches completion from one that is ready, compliant, controlled, and operationally effective.

About The Author:

Tobias Kuners of Koenders is managing consultant at Tob Management, a Netherlands-based consulting firm providing business and technical expertise to the pharmaceutical, biotech, medical device, and FSMP (food for special medical purpose) industries. He has worked with Biogen, Ipsen, Thermo Fisher, Kite Pharma, and Danone, among other companies, gaining hands-on experience in engineering services, equipment qualification, maintenance, supply chain, warehousing, and distribution. He has led design, engineering, and construction of multiple facilities to meet cGMP requirements. He performs audits, identifies gaps, and develops remediation plans, working within organizations to assist with deviation investigations and CAPA implementation and to develop scientific, risk-based solutions. You can contact him at [email protected].